We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| OpGen Inc | NASDAQ:OPGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.96 | 1.86 | 1.97 | 0 | 01:00:00 |
From Oct 2019 to Oct 2024
OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?” on Friday, September 9 from 1:40 p.m. to 2:20 p.m. ET. The roundtable will feature Bert Lopansri, M.D., Associate Professor of Medicine, University of Utah; Chief of Infectious Diseases, Intermountain Healthcare; and Medical Director, Urban Central Region Microbiology Lab, Division of Infectious Diseases and Epidemiology.
About OpGenOpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
Hot Features
Premium
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor Relations
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com
OpGen Media
MacDougall Biomedical Communications
Cammy Duong
781-235-3060
cduong@macbiocom.com
1 Year OpGen Chart |
1 Month OpGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
